Resistance Distribution profile of MBL, ESBL and Multidrug resistant Gram negatives isolated at a tertiary care hospital in India

摘要

Prevalence of extended spectrum β-lactamase (ESBLs) and metallo- β -lactamase (MBLs) constitute a serious threat to current β-lactam therapy leading to treatment failure and consequent escalation of cost. In a tertiary care hospital the patients are admitted for causes other than the underlying infection. Detection of infection and subsequent identification of resistance in the infectious agent puts additional burden of investigating effective drug for cure. To ease the process of drug selection to treat MBL and ESBL isolates a detailed study was initiated to identify the resistance distribution pattern in isolates. In a year long study a total of 390 isolates were found to contain 35.12% ESBLs, 9.48% MBLs, 32.56% multidrug resistants and the rest sensitive. Only a lone isolate was found to be both ESBL as well as MBL producer. In this study we also noted that all ESBLs were sensitive to cefoperazome+sulbactum, piperacilin+tazobactam and imipenem, MBLs were sensitive to polymixin-B and imipenem+cilastatin combination and multidrug resistants were found to respond well to carbapenems and polymixin-B.